Filing 2022 Q2 compared to 2022 Q1 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Jennifer Ciresi
General Counsel and Chief Compliance Officer
San Francisco, California
15 Aug 2022
The attached information table excludes (a) 1,692 shares of common stock of IGM BIOSCIENCES INC issued pursuant to restricted stock unit awards and (b) 2,681 shares of common stock of FATE THERAPEUTICS INC issued pursuant to restricted stock unit awards.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.